ReachMD

ReachMD CME

Science EN ↓ 544 episodes

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Be sure to visit the podcast's website and support the creator: reachmd.com

Author

ReachMD

Episodes

Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma 31.07.2025 5:30

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-and-practice-changing-data-in-immunotherapy-strategies-for-melanoma/36330/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melan...

Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma 31.07.2025 5:30

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-data-prompting-guideline-updates-for-subcutaneous-icis-in-melanoma/36329/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melano...

Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma 31.07.2025 5:00

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-braf-mutant-stage-iv-melanoma/36328/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical st...

Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma 31.07.2025 5:45

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/data-driving-preferred-guideline-recommendations-in-first-line-therapy-for-metastatic-melanoma/36327/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies...

Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma 31.07.2025 5:30

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-stage-iii-melanoma/36326/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies fo...

Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma 31.07.2025 5:00

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iiiiv-melanoma/36325/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into p...

Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma 31.07.2025 4:45

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iibiic-melanoma/36324/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into...

Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma 31.07.2025 5:45

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-implications-of-neoadjuvant-therapy-guideline-updates-in-resectable-melanoma/36323/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treat...

Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma 31.07.2025 5:15

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/data-driving-recent-guideline-updates-in-neoadjuvant-therapy-for-resectable-melanoma/36322/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treati...

Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC 31.07.2025 5:00

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapeutic-developments-in-non-targetable-metastatic-nsclc/36153/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate,...

MET and Other Emerging Targets in Metastatic NSCLC 31.07.2025 6:45

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/met-and-other-emerging-targets-in-metastatic-nsclc/36152/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is...

HER2-Driven Strategies in Metastatic NSCLC 31.07.2025 8:00

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/her2-driven-strategies-in-metastatic-nsclc/36151/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essenti...

Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC 31.07.2025 12:30

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/finding-the-optimal-treatment-for-egfr-mutated-metastatic-nsclc/36150/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, stayi...

Strategies in EGFR-mutated Unresectable Stage III NSCLC 31.07.2025 5:00

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/strategies-in-egfr-mutated-unresectable-stage-iii-nsclc/36149/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying curre...

The Current Therapeutic Landscape in Unresectable Stage III NSCLC 31.07.2025 4:30

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-current-therapeutic-landscape-in-unresectable-stage-iii-nsclc/36148/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, sta...

Applications of Emerging Data in Resectable NSCLC 31.07.2025 7:30

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/applications-of-emerging-data-in-resectable-nsclc/36147/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is...

Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) 31.07.2025 9:15

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/novel-therapies-in-extensive-stage-small-cell-lung-cancer-es-sclc/36146/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, sta...

Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC) 31.07.2025 7:30

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/updates-in-limited-stage-small-cell-lung-cancer-ls-sclc/36145/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying curre...

Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy 30.07.2025 35:15

CME credits: 0.50 Valid until: 30-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/addressing-ckm-mortality-morbidity-in-patients-with-ckd-and-t2d-the-role-of-combined-ns-mra-sglt2i-therapy/29907/ This three-part panel series explores how emerging evidence from the CONFIDENCE trial is shaping the future of cardio-kidney-metabolic (CKM) care. In Chapter 1, the experts discuss the a...

ADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer 29.07.2025 16:46

CME credits: 0.25 Valid until: 29-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/adcs-across-the-spectrum-of-her2-expression-in-metastatic-breast-cancer/32202/ In this Virtual Case Clinic, explore three patient case examples with Dr. Mahtani as she demonstrates the application of the latest clinical evidence in HER2-positive, HER2-low, and HER2-ultralow metastatic breast cancer....

Expert Recommendations and Key Takeaways 25.07.2025 5:30

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/expert-recommendations-and-key-takeaways/36186/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for tre...

Ongoing Clinical Trials in AML With Menin Inhibitors 25.07.2025 5:15

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/ongoing-clinical-trials-in-aml-with-menin-inhibitors/36185/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strate...

Emerging Directions in Menin-Directed AML Therapy 25.07.2025 5:30

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-directions-in-menin-directed-aml-therapy/36184/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategie...

Applying Evidence to Clinical Practice 25.07.2025 5:15

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/applying-evidence-to-clinical-practice/36183/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treat...

Managing Adverse Events Associated With Menin Inhibitors 25.07.2025 4:15

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-adverse-events-associated-with-menin-inhibitors/36182/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based st...